Name
GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease.
Date & Time
Friday, December 13, 2024
Speakers
Virtual Session Link
Total Minutes
11:41
OnDemand Video URL